Grindeks                                                        05.12.2005



JSC Grindeks receives new patents of medicaments



On the 1st of December this year JSC Grindeks signed an agreement on 

acquisition of patents – combination of new medicines for the treatment of 

cardiovascular diseases.



Newly obtained patents will protect medicines manufactured by Grindeks in 

5 states – in Latvia, Russia, Kazakhstan, Byelorussia and Ukraine. In the 

near future these patents will be registered on possession of Grindeks.



On the 20th November 2005 Patent Office of the Republic of Latvia published 

in its official bullet and on the 28th of November issued to JSC Grindeks two 

patents, which will enhance strengthening the company’s portfolio of 

intellectual property and in future will deliver a substantial contribution 

to cardiology.



“This isn’t the only State where the new products will be protected. We have 

started preparation works for the submission of the international patent 

application to the regional and national registration referable to more than 

60 countries,” emphasizes Valdis Jākobsons, Chairman of the Board, 

JSC Grindeks. “Our company pays attention not only to the protection of the 

innovations but also works hard on the fast arrival of the proprietary products 

to the markets of Latvia and other countries. Pharmacy is the sphere with 

highest regulations and many different tests as well as complex registration 

process is held before the product gets to the consumer.”  



Presently JSC Grindeks is working on the other research projects for the 

improvement of the company product portfolio.  



"New patents are a logical outcome of long-term research works that demands 

large material investments and highly qualified personnel. We are certain 

than already in the nearest future JSC Grindeks will begin extensive patenting 

of the next innovations that are now being developed”, accents V. Jākobsons. 

" JSC Grindeks is fully aware of the fact that the times when production of 

large amount, cheap medications were important are gone. Nowadays in the 

pharmaceutical industry the companies having products whose intellectual 

property are protected with patents and trade marks are the successful ones.”    



Duration of the patent in Latvia is 20 years starting from the application 

date in the Patent Office of the Republic of Latvia. 





Information prepared by:

Finance and Administrative director

JSC Grindeks

Office: 7083250, 

GSM:  9226767

e-mail: janis_romanovskis@grindeks.lv